These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19192989)

  • 1. In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US.
    Dansereau RJ; Crail DJ; Perkins AC
    Curr Med Res Opin; 2009 Feb; 25(2):449-52. PubMed ID: 19192989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications.
    Dansereau RJ; Crail DJ; Perkins AC
    Curr Med Res Opin; 2008 Apr; 24(4):1137-45. PubMed ID: 18334082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
    Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
    Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
    Walker AD; Adachi JD
    Curr Med Res Opin; 2011 Sep; 27(9):1749-54. PubMed ID: 21781014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disintegration/dissolution profiles of copies of Fosamax (alendronate).
    Epstein S; Cryer B; Ragi S; Zanchetta JR; Walliser J; Chow J; Johnson MA; Leyes AE
    Curr Med Res Opin; 2003; 19(8):781-9. PubMed ID: 14687450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate.
    Shakweh M; Bravo-Osuna I; Ponchel G
    Eur J Pharm Sci; 2007 Aug; 31(5):262-70. PubMed ID: 17576054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Process analytical technology to understand the disintegration behavior of alendronate sodium tablets.
    Xu X; Gupta A; Sayeed VA; Khan MA
    J Pharm Sci; 2013 May; 102(5):1513-23. PubMed ID: 23450666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment on Disintegration/dissolution profiles of copies of Fosamax (alendronate).
    Bolaños Díaz R
    Curr Med Res Opin; 2004 Jul; 20(7):1035-6; author reply 1036-7. PubMed ID: 15265248
    [No Abstract]   [Full Text] [Related]  

  • 9. A critical review of brand and generic alendronate for the treatment of osteoporosis.
    Brown JP; Davison KS; Olszynski WP; Beattie KA; Adachi JD
    Springerplus; 2013; 2(1):550. PubMed ID: 25674402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in In Vitro Disintegration Time among Canadian Brand and Generic Bisphosphonates.
    Olszynski WP; Adachi JD; Davison KS
    J Osteoporos; 2014; 2014():420451. PubMed ID: 25349772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of simvastatin tablets from the US and international markets obtained via the Internet.
    Veronin MA; Nguyen NT
    Ann Pharmacother; 2008 May; 42(5):613-20. PubMed ID: 18413690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
    Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly J; Fischer MA; Kesselheim AS; Gagne JJ
    BMJ; 2018 Apr; 361():k1180. PubMed ID: 29615391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic alendronate use among Medicare beneficiaries: are Part D data complete?
    Yun H; Curtis JR; Saag K; Kilgore M; Muntner P; Smith W; Matthews R; Wright N; Morrisey MA; Delzell E
    Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):55-63. PubMed ID: 23135758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro determination of the release of alendronic acid from alendronate tablets of different brands during deglutition.
    Lamprecht G
    J Pharm Sci; 2009 Oct; 98(10):3575-81. PubMed ID: 19630066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of palatability of 10 commercial amlodipine orally disintegrating tablets by gustatory sensation testing, OD-mate as a new disintegration apparatus and the artificial taste sensor.
    Uchida T; Yoshida M; Hazekawa M; Haraguchi T; Furuno H; Teraoka M; Ikezaki H
    J Pharm Pharmacol; 2013 Sep; 65(9):1312-20. PubMed ID: 23927469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new modified wetting test and an alternative disintegration test for orally disintegrating tablets.
    Hooper P; Lasher J; Alexander KS; Baki G
    J Pharm Biomed Anal; 2016 Feb; 120():391-6. PubMed ID: 26774944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esophageal irritation due to alendronate sodium tablets: possible mechanisms.
    Peter CP; Handt LK; Smith SM
    Dig Dis Sci; 1998 Sep; 43(9):1998-2002. PubMed ID: 9753265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the disintegration properties of commercial famotidine 20 mg orally disintegrating tablets using a simple new test and human sensory test.
    Harada T; Narazaki R; Nagira S; Ohwaki T; Aoki S; Iwamoto K
    Chem Pharm Bull (Tokyo); 2006 Aug; 54(8):1072-5. PubMed ID: 16880646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical disintegration time of orally disintegrating tablets clinically available in Japan in healthy volunteers.
    Yoshita T; Uchida S; Namiki N
    Biol Pharm Bull; 2013; 36(9):1488-93. PubMed ID: 23995661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of generic preparations of famotidine orally disintegrating tablets for use in unit-dose packages.
    Yamazaki N; Iizuka R; Miyazawa S; Wada Y; Shimokawa K; Ishii F
    Drug Discov Ther; 2012 Oct; 6(5):263-8. PubMed ID: 23229147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.